Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split (PRNewswire) - Jun 26, 2026 - "The Company also reaffirmed its guidance for the dosing of the initial five patients in the TakeAim CLL study by the end of July 2026, with data expected in December 2026."
Enrollment open • P2 data • Chronic Lymphocytic Leukemia
|